Overview

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Status:
Completed
Trial end date:
2018-01-03
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Budesonide
Fluticasone
Formoterol Fumarate
Mometasone Furoate
Salmeterol Xinafoate
Xhance